While its specific molecular target or pathway has not yet been determined, studies have shown that modulating inflammation may contribute to reducing tau aggregation and the progression of Alzheimer’s disease (AD) [41]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.